

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 January 2007 (11.01.2007)

PCT

(10) International Publication Number
WO 2007/005534 A3

(51) International Patent Classification:

A61K 31/404 (2006.01) C07D 221/02 (2006.01)

A61K 31/435 (2006.01)

(21) International Application Number:

PCT/US2006/025402

(22) International Filing Date: 28 June 2006 (28.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/695,256 30 June 2005 (30.06.2005) US

(71) Applicant (for all designated States except US):

SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia,
PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DENG, Jianghe**

[CN/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **KERNS, Jeffrey, K.** [US/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **JIN, Qi** [CN/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **LIN, Guoliang** [CN/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **LIN, Xichen** [CN/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **LINDENMUTH, Michael** [US/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **NEIPP, Christopher, E.** [US/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **NIE, Hong** [CN/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **THOMAS, Sonia, M.** [US/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **WIDDOWSON, Katherine, L.** [CA/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US).

(74) Agents: **MADDEN, Laura, K.** et al.; GLAXOSMITHK-

LINE, CORPORATE INTELLECTUAL PROPERTY,
UW2220, 709 Swedeland Road, P.O. Box 1539, King Of
Prussia, PA 19406-0939 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:


- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

26 April 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL COMPOUNDS



(57) **Abstract:** The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: Formula (I) where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK β) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the

invention or a pharmaceutical composition comprising a compound of the invention.